Back

Heart failure & diabetes: SGLT2 inhibition, a paradigm shift?

28 August 2016 (13:25 - 13:40)
Organised by:
Congress Presentation Part of: SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management? Diabetes management ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor John J V McMurray

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Introduction - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?
Doctor D. Fitchett (Toronto, CA)
Presentation thumbnail
Challenging CV Risk in diabetes: ready for a new approach?
Professor J. Deanfield (London, GB)
Presentation thumbnail
SGLT-2 inhibitors in T2DM management: current position & future promise.
Professor S. Inzucchi (New Haven, US)
Presentation thumbnail
Panel discussion - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?
Doctor D. Fitchett (Toronto, CA) Professor J. McMurray (Glasgow, GB)

Access the full session

Session thumbnail
SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

The Event

Event poster

ESC Congress 2016

28 August 2016 13:25 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources